TABLE 1.
Effects of ACV and HDP-P-ACV on serum WHV DNA levels in WHV infection
| Treatmenta | 109 WHV genomes/ml of serum ± SD at:
|
% Changeb ± SD at:
|
P vs placeboc
|
||||
|---|---|---|---|---|---|---|---|
| Time zero | 4 Wks | Nadir | 4 Wks | Nadir | At 4 wks | Maximum | |
| Expt 1 | |||||||
| Placebo | 234 ± 221 | 212 ± 165 | 166 ± 90 | +14 ± 65 | +2.3 ± 84 | ||
| ACV (20 mg/kg b.i.d.) | 167 ± 96 | 127 ± 69 | 88 ± 40 | −15 ± 33 | −39 ± 22 | NS | NS |
| HDP-P-ACV (10 mg/kg b.i.d.) | 86 ± 77 | 3.7 ± 4.7 | 3.7 ± 4.7 | −95 ± 9 | −95 ± 8.5 | <0.05 | <0.05 |
| HDP-P-ACV (20 mg/kg b.i.d.) | 282 ± 165 | 89 ± 120 | 42 ± 39 | −66 ± 38 | −84 ± 12 | <0.05 | <0.05 |
| Expt 2 | |||||||
| Placebo | 17.0 ± 11.7 | 29.3 ± 19.1 | 29.4 ± 18.8 | +61 ± 43 | +72 ± 28 | ||
| HDP-P-ACV (5 mg/kg b.i.d.) | 34.0 ± 14.5 | 11.3 ± 12.8 | 5.36 ± 4.78 | −72 ± 21 | −86 ± 8.2 | <0.001 | <0.001 |
| HDP-P-ACV (30 mg/kg q.d.) | 47.3 ± 42.0 | 22.0 ± 22.6 | 16.5 ± 20.1 | −58 ± 13 | −72 ± 13 | <0.001 | <0.001 |
a
The number of animals in each group was four in every instance.
b
By using each WHV-infected animal as its own control, the percent change from time zero was calculated for each animal at 4 weeks and also for the nadir observed during weeks 1 through 6.
c
The means ± standard deviations of the percent change at 4 weeks and the maximal percent change (weeks 1 through 6) were calculated and tested for statistical significance versus values for the placebo by using the Student-Newman-Keuls multiple comparisons test (Instat2; Graphpad Software, San Diego, Calif.). NS, not significant.